Ascletis' vision is to become the most innovative world-class biomedical company. Ascletis is committed to developing and commercializing innovative drugs in the areas of viral diseases, metabolic diseases, and cancer (oral cancer metabolic checkpoint and immune checkpoint inhibitors) to address unmet medical needs both in China and globally.
Our values guide us in how we do business and how we work together internally, and externally with our domestic and global partners.
Eliminate viral hepatitis as a major public health threat by 2030.
World Health OrganizationAscletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline.
Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscl......
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose ......
Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, ......
Our greatest assets are our employees. Ascletis is an equal opportunity employer and focused on providing a positive work environment where courageous innovation is encouraged and expected.
Ascletis' vision is to become the most innovative world-class biomedical company addressing global unmet medical needs in the area of metabolic diseases.
We offer competitive salaries and benefits that reward employees for their contribution to the company. If you’re interested in learning more about what we have to offer, please email your CV to hr@ascletis.com. We will look to match any current and upcoming openings to your area of expertise.
© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号
浙ICP备11050387号-1
